|
gptkbp:instanceOf
|
gptkb:drug
bile acid analog
|
|
gptkbp:approvalYear
|
2016
|
|
gptkbp:ATCCode
|
gptkb:A05AA04
|
|
gptkbp:brand
|
gptkb:Ocaliva
|
|
gptkbp:CASNumber
|
gptkb:459789-99-2
|
|
gptkbp:contraindication
|
complete biliary obstruction
|
|
gptkbp:developer
|
gptkb:Intercept_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
6 days
|
|
gptkbp:hasMolecularFormula
|
C26H44O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
obeticholic acid
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
farnesoid X receptor agonist
|
|
gptkbp:pregnancyCategory
|
Not assigned (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105721
gptkb:DB11599
11219336
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
abdominal pain
fatigue
pruritus
rash
arthralgia
oropharyngeal pain
|
|
gptkbp:status
|
FDA approved for primary biliary cholangitis
|
|
gptkbp:synonym
|
6-ethylchenodeoxycholic acid
|
|
gptkbp:UNII
|
6ZY7X42A4I
|
|
gptkbp:usedFor
|
gptkb:nonalcoholic_steatohepatitis
gptkb:primary_biliary_cholangitis
|
|
gptkbp:bfsParent
|
gptkb:Primary_Biliary_Cholangitis
|
|
gptkbp:bfsLayer
|
5
|